GU
Guizhou Utide Biotechnology Co., Ltd.
CDMO · Zunyi, China
Overview
Utide Biotechnology is in Zunyi, Guizhou. Its site says its first facility started operating in 2023, reached kilogram-scale output in 2024 and about 400 kg a year in 2025, with a 2,000 kg-per-year base added in 2026. It offers peptide development and manufacturing services and lists research peptides such as BPC-157, MOTS-c, KPV, Semax and Selank alongside tirzepatide and retatrutide. The FDA DMF list shows an active Type II DMF for tirzepatide (the same list also shows DMFs in its name for retatrutide, BPC-157, MOTS-c and KPV). It describes its quality system as GMP-aligned; no regulator inspection is cited.
Capabilities
- Tirzepatide API
- Retatrutide and research peptides
- Process development and scale-up
- Kg-scale peptide manufacturing
Quality signals
| GMP evidence | Not found |
|---|---|
| Certificates of analysis | Not found |
| Third-party testing | Not found |
| ISO certification | Not found |
| Makes own product | Yes, in-house production |